Published in Blood on August 06, 2010
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer (2012) 4.97
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood (2011) 4.43
Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia (2013) 2.85
Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol (2011) 2.69
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood (2011) 2.47
The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell (2013) 2.33
Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell (2014) 2.15
Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood (2014) 1.82
Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol (2014) 1.58
Clonal evolution in hematological malignancies and therapeutic implications. Leukemia (2013) 1.50
The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat Rev Cancer (2012) 1.27
Connections between TET proteins and aberrant DNA modification in cancer. Trends Genet (2014) 1.24
Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Haematologica (2011) 1.21
Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. J Clin Invest (2011) 1.16
COLD-PCR enrichment of rare cancer mutations prior to targeted amplicon resequencing. Clin Chem (2011) 1.14
Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes. Haematologica (2013) 1.13
TET proteins and the control of cytosine demethylation in cancer. Genome Med (2015) 1.13
Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome. Haematologica (2013) 1.11
The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome. Nat Genet (2015) 1.05
Molecular biology of myelodysplastic syndromes. Semin Oncol (2011) 1.01
A new branch on the tree: next-generation sequencing in the study of cancer evolution. Semin Cell Dev Biol (2012) 1.00
TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia. PLoS One (2012) 0.98
Driver mutations of cancer epigenomes. Protein Cell (2014) 0.98
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. Haematologica (2015) 0.94
Molecular pathophysiology of myelodysplastic syndromes. Annu Rev Pathol (2012) 0.94
Iron and thiols as two major players in carcinogenesis: friends or foes? Front Pharmacol (2014) 0.91
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event. Leukemia (2015) 0.89
Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations. Haematologica (2013) 0.87
Age-related mutations and chronic myelomonocytic leukemia. Leukemia (2015) 0.86
Tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome. Rev Bras Hematol Hemoter (2014) 0.85
Epigenetic alterations and microRNAs: new players in the pathogenesis of myelodysplastic syndromes. Epigenetics (2013) 0.84
TET2 mutations in secondary acute myeloid leukemias: a French retrospective study. Haematologica (2011) 0.83
The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication? Expert Rev Hematol (2013) 0.81
Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease. Blood Res (2014) 0.80
TET2 Expression in Bone Marrow Mononuclear Cells of Patients with Myelodysplastic Syndromes and Its Clinical Significances. Cancer Biol Med (2012) 0.80
I walk the line: how to tell MDS from other bone marrow failure conditions. Curr Hematol Malig Rep (2014) 0.79
Applicability of next-generation sequencing to decalcified formalin-fixed and paraffin-embedded chronic myelomonocytic leukaemia samples. Int J Clin Exp Pathol (2014) 0.79
Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer. Ann Oncol (2014) 0.79
Genomic tools in acute myeloid leukemia: From the bench to the bedside. Cancer (2014) 0.79
Emerging concepts of epigenetic dysregulation in hematological malignancies. Nat Immunol (2016) 0.79
Chronic myelomonocytic leukemia: Forefront of the field in 2015. Crit Rev Oncol Hematol (2015) 0.78
The search for better prognostic models in myelodysplastic syndromes. Curr Hematol Malig Rep (2011) 0.77
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Blood Cancer J (2011) 0.77
Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies. Oncotarget (2016) 0.77
Histone methylation in myelodysplastic syndromes. Epigenomics (2011) 0.77
TET2 overexpression in chronic lymphocytic leukemia is unrelated to the presence of TET2 variations. Biomed Res Int (2014) 0.76
TET2 Inhibits Differentiation of Embryonic Stem Cells but Does Not Overcome Methylation-Induced Gene Silencing. Bone Marrow Res (2014) 0.75
T cells of patients with myelodysplastic syndrome are frequently derived from the malignant clone. Br J Haematol (2012) 0.75
Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features. Oncotarget (2016) 0.75
Metabolism pathways in chronic lymphocytic leukemia. Leuk Lymphoma (2015) 0.75
Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights. Oncol Rev (2016) 0.75
Molecular basis of myelodysplastic syndromes. Leuk Suppl (2012) 0.75
Prognostic role of TET2 deficiency in myelodysplastic syndromes: A meta-analysis. Oncotarget (2017) 0.75
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol (2009) 12.41
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature (2010) 8.87
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol (2007) 7.34
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol (2009) 6.54
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood (2007) 5.80
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol (2010) 4.72
Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood (2009) 4.64
Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med (2012) 4.15
Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood (2007) 3.89
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol (2012) 3.88
Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med (2003) 3.64
250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res (2008) 3.51
Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. N Engl J Med (2015) 3.42
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood (2010) 3.15
Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood (2007) 3.13
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica (2011) 3.11
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood (2013) 2.97
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res (2007) 2.97
TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol (2011) 2.88
Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood (2012) 2.88
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood (2008) 2.87
Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene (2005) 2.80
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.76
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica (2008) 2.69
Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst (2008) 2.64
STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood (2012) 2.55
CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood (2011) 2.52
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood (2012) 2.51
SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood (2012) 2.50
In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet (2004) 2.47
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood (2011) 2.47
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood (2007) 2.37
Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res (2013) 2.24
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood (2004) 2.23
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell (2013) 2.22
An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood (2011) 2.16
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica (2010) 2.14
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
Somatic SETBP1 mutations in myeloid malignancies. Nat Genet (2013) 2.12
Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood (2009) 2.11
JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica (2008) 2.05
Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol (2009) 2.04
Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol (2009) 2.03
Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol (2011) 2.02
CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood (2008) 2.00
Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. Am J Clin Pathol (2006) 1.90
TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol (2013) 1.87
SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD. PLoS One (2007) 1.87
Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res (2006) 1.83
Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood (2013) 1.80
CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood (2007) 1.80
Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Biol Blood Marrow Transplant (2012) 1.80
Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol (2011) 1.79
Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood (2008) 1.78
Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol (2009) 1.74
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica (2009) 1.73
Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet (2013) 1.71
Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood (2004) 1.70
Valproic acid for the treatment of myeloid malignancies. Cancer (2007) 1.69
Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) with reversed-phase protein arrays for protein profiling. Clin Chem Lab Med (2005) 1.68
New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. J Clin Oncol (2009) 1.68
Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol (2013) 1.68
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer (2006) 1.65